Skip to main content
Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions
- Albrecht, J Mark;
- Cooper, Benjamin R;
- Waller, Jacquelyn D;
- Presley, Colby L;
- Pulsipher, Kayd J;
- Rundle, Chandler W;
- Dellavalle, Robert P
- et al.
© 2023 by the author(s). Learn more.
Published Web Locationhttps://doi.org/10.5070/D329160209
Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
Fast Web View:
Preparing document for printing…